Galena Biopharma Announces Department of Defense Grant for NeuVax Clinical Trial

Galena Biopharma , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the Department of Defense will provide funding towards a new clinical trial with NeuVax to prevent breast cancer recurrence in high-risk HER2 3+ ... (more)

http://ift.tt/QPdCOj